Abstract
GC-MS of tissue extracts obtained from a parkinsonian patient who died from secondary causes during memantine (l-amino-3.5-dimethyl- adamantane) treatment showed the drug to be largely unmetabolized. In the kidney and liver a second peak corresponded to less than 1% of the main peak. In the brain an accumulation of memantine could be shown in the temporal lobe, hypothalamus and pons. Thus treatment with 2×10 mg memantine/day reveals an accumulation of the drug in µM concentrations in the brain. This is probably high enough to explain the ameliorating effect of memantine treatment in patients suffering from Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bleidner, W. EHarmon, J. B., Hewes, W. E., Lynes, T. E., Hermann, E. C.: Absorption, distribution and excretion of amantadine hydrochloride. J. Pharmacol. Exp. Therap. 150, 484–490 (1965).
Cupp, J., Klymkowski, M., Sands, J, Reith, A., Snipes, W.: Effect of lipid alkyl diain perturbations on the assembly of bacteriophage PM 2. Bio- chim. Biophys. Acta 389, 345–357 (1975).
Eletr, S., Williams, M. A., Watkins, T., Reith, A. D.: Perturbations of the dynamics of lipid alkyl chains in membrane systems: Effect on the activity of membrane-bound enzymes. Biochim. Biophys. Acta 339, 190–201 (1974).
Fischer, P.-A., Jacobi, P., Schneider, E., Schönberger, D.: Die Wirkung intravenöser Gaben von Memantin bei Parkinson-Kranken. Arzneim.-Forsch. (Drug Res.) 27, 1487–1489 (1977).
Fünfgeld, E. W.: 33 Monate Therapie mit Dimethylaminoadamantan. Unpublished paper (1975).
Fünfgeld, E. W.: Konservative Behandlung des Parkinsonismus. Vortrag und Film. Medizin. Gesellschaft Freiburg/Breisgau, February 3, 1976.
Grossmann, W., Jurna, J.: Die Wirkung von Memantin auf die Membranen sensibler Nervenfaserbündel. Arzneim.-Forsch. (Drug Res.) 27, 1483 to 1487 (1977).
Maj, J., Marchaj, J., Mogilnicka, E.: The effect of dimethyladamantane on the brain 5-hydroxytryptamine and 5-hydroxyindoleacetic acid levels. Second Congr. Hung. Pharmacol. Soc. Budapest, 1974.
Maj, J., Dopaminergic drugs and Serotonin neurons. In: Current Developments in Psydhopharmacology (Essman, W. B., Valzelli, L., eds.), Vol. 3, pp. 55–83. NewYork-Toronto-London-Sydney: Spectrum. 1976.
Svensson, T. H.: Dopamine release and direct dopamine receptor activation in the central nervous system by D 145, an amantadine derivative. Eur. J. Pharmacol. 23, 232–238 (1973).
Wesemann, W., Schollmeyer, J. D., Sturm, G.: Gaschromatographische und massenspektrometrische Untersuchungen über harnpflichtige Metaboliten von Adamantanaminen. Arzneim.-Forsch. (Drug Res.) 27, 1471–1476 (1977).
Wesemann, W., Dette-Wildenhahn, G., Fellehner, H.: In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson. J. Neural Transm. 44, 263–285 (1979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag
About this chapter
Cite this chapter
Wesemann, W., Sturm, G., Fünfgeld, E.W. (1980). Distribution and Metabolism of the Potential Anti-Parkinson Drng Memantine in the Human. In: Carlsson, A., Jellinger, K., Riederer, P. (eds) Current Topics in Extrapyramidal Disorders. Journal of Neural Transmission, vol 16. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8582-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8582-7_15
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-8584-1
Online ISBN: 978-3-7091-8582-7
eBook Packages: Springer Book Archive